TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05635019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BWL+VOUCHER
Description: This group will receive the BWL program as well as food vouchers, in the form of grocery store gift cards. Participants will be allowed to select to receive gift cards to a grocery store or supermarket from a pre-determined list of stores. Gift cards worth $40 will be emailed or mailed to every 2 weeks after the BWL session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BWL+HOME
Description: This group will receive the BWL program as well as home-delivered boxes of groceries of low-energy density foods conducive to weight management guidelines. Groceries will include shelf-stable and perishable products like lean meats, fresh vegetables, and fruits. Every 2 weeks, participants assigned to this group will be allowed to select a choice of one of 4 boxes with slightly varied contents. Each box will have approximately $40 worth of groceries.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss counseling (BWL)
Description: The behavioral weight loss program consists of 14 individual lifestyle counseling sessions provided over 24 weeks. Each session will be approximately 15-20 minutes. Visits will be scheduled weekly for the first 4 weeks (weeks 1, 2, 3, and 4) and every-other week from weeks 6-24 (weeks 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24). The sessions will provide behavioral, dietary, and physical counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss counseling (BWL)
Description: The behavioral weight loss program consists of 14 individual lifestyle counseling sessions provided over 24 weeks. Each session will be approximately 15-20 minutes. Visits will be scheduled weekly for the first 4 weeks (weeks 1, 2, 3, and 4) and every-other week from weeks 6-24 (weeks 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24). The sessions will provide behavioral, dietary, and physical counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral weight loss counseling (BWL)
Description: The behavioral weight loss program consists of 14 individual lifestyle counseling sessions provided over 24 weeks. Each session will be approximately 15-20 minutes. Visits will be scheduled weekly for the first 4 weeks (weeks 1, 2, 3, and 4) and every-other week from weeks 6-24 (weeks 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24). The sessions will provide behavioral, dietary, and physical counseling.
Study: NCT06271993

Intervention type: DEVICE
Group type: OTHER
Intervention: ColActivePlus Collagen Matrix Dressing
Description: The test product, positive control and negative control will be applied directly to the volar forearm skin of the subject. The sites will be a minimum of 2cm from each other to minimize cross contamination.
Study: NCT06100809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized coaching
Description: Personalized fatigue mitigation coaching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition handout
Description: Nutrition handout

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition handout
Description: Nutrition handout
Study: NCT06177080

Intervention type: OTHER
Group type: OTHER
Intervention: transperineal ultrasound
Description: descent angle and head symphysis distances by transperineal ultrasound of active phase of labor women.
Study: NCT04561206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05002127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evorpacept (ALX148)
Description: IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evorpacept (ALX148)
Description: IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: IV Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: IV Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: IV Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Days 1, 8, and 15 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV Days 1, 8, and 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Days 1, 8, and 15 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV Days 1, 8, and 15 of a 28-day cycle
Study: NCT05618613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant 200mg, 300mg, or 400mg once daily oral dosing in cycles of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onapristone
Description: Onapristone 40mg or 50mg twice daily oral dosing in cycles of 28 days.
Study: NCT04701814

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: biomechanical scapular mobilization with movement and motor learning
Description: the therapist applied posterior tilt and exteral rotation with upward rotation mobilization to scapula and therapist also warp bilt around GH joint to applied inferior and posterior glid then ask patient to elevate his arm. then we applied motor learning approach by asking patient to elevate his arm with maintaining of external rotation with posterior glid of scapula.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: biomechanical scapular mobilization with movement and motor learning
Description: the therapist applied posterior tilt and exteral rotation with upward rotation mobilization to scapula and therapist also warp bilt around GH joint to applied inferior and posterior glid then ask patient to elevate his arm. then we applied motor learning approach by asking patient to elevate his arm with maintaining of external rotation with posterior glid of scapula.
Study: NCT05929963

Intervention type: OTHER
Intervention: HCV infection status
Description: Divided into 3 groups based on HCVAb and HCVRNA status

Intervention type: OTHER
Intervention: HCV infection status
Description: Divided into 3 groups based on HCVAb and HCVRNA status

Intervention type: OTHER
Intervention: HCV infection status
Description: Divided into 3 groups based on HCVAb and HCVRNA status
Study: NCT05405062

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxytherapy, short pulsed 1064 Nd Yag laser and subcision
Description: Carboxytherapy is involves the injection of carbon dioxide into the subcutaneous tissue, with the goal of affecting the adipose tissue and circulation. Its mechanism of action is through an increase in capillary blood flow induced by hypercapnia and a decrease in cutaneous oxygen consumption (Pianez et al., 2016).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxytherapy, short pulsed 1064 Nd Yag laser and subcision
Description: Carboxytherapy is involves the injection of carbon dioxide into the subcutaneous tissue, with the goal of affecting the adipose tissue and circulation. Its mechanism of action is through an increase in capillary blood flow induced by hypercapnia and a decrease in cutaneous oxygen consumption (Pianez et al., 2016).
Study: NCT05823363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel with Bubivacaine
Description: 10ml Exparel mixed with10ml bupivicaine in vaginal cuff

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine only
Description: 20ml of Bubivacaine in the vaginal cugg
Study: NCT05383118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components:~1. One multimedia e-learning lesson on promoting brain health and preventing dementia;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to dementia risk factors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Control
Description: Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components:~1. One multimedia e-learning lesson on mild cognitive impairment;~2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson.~3. Curated resources related to mild cognitive impairment
Study: NCT06331013

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife ultra-hypofractionated SBRT
Description: CyberKnife ultra-hypofractionated SBRT for localized Prostate cancer with dose-escalation to the dominant intraprostatic lesion
Study: NCT05118945

Intervention type: DEVICE
Intervention: Insulin pump Tandem: t:slim X2
Description: Insulin pump with Hybrid-Closed Loop - Modus. The insulin pump t:slim X2 from the manufacturer Tandem, in cooperation with the glucose sensor DexCom G6, has the option of using an algorithm called control IQ, which controls the insulin delivery semi-automatically by means of an MPC algorithm. For this purpose, the insulin basal delivery can be increased or decreased by the system. Furthermore, automatic bolus deliveries, which are possible in the amount of up to 60% of a manual correction, can be delivered.

Intervention type: DEVICE
Intervention: Insulin pump Tandem: t:slim X2
Description: Insulin pump with Hybrid-Closed Loop - Modus. The insulin pump t:slim X2 from the manufacturer Tandem, in cooperation with the glucose sensor DexCom G6, has the option of using an algorithm called control IQ, which controls the insulin delivery semi-automatically by means of an MPC algorithm. For this purpose, the insulin basal delivery can be increased or decreased by the system. Furthermore, automatic bolus deliveries, which are possible in the amount of up to 60% of a manual correction, can be delivered.
Study: NCT04919109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CodaVax-RSV
Description: live attenuated vaccine against RSV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CodaVax-RSV
Description: live attenuated vaccine against RSV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CodaVax-RSV
Description: live attenuated vaccine against RSV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CodaVax-RSV
Description: live attenuated vaccine against RSV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo comparator
Study: NCT03546309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC group
Description: Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.

Intervention type: OTHER
Group type: OTHER
Intervention: Medication group
Description: Patients allocated to Medication group will accept medication treatment by professional neurologists
Study: NCT06490289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denpro oral gel
Description: Experimental group was given Denpro oral gel (Gennec Health Sciences PVT, LTD, Karachi, Pakistan)
Study: NCT04593784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciraparantag
Description: Ciraparantag: 180 mg, intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciraparantag
Description: Ciraparantag: 180 mg, intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciraparantag
Description: Ciraparantag: 180 mg, intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 0.9% sodium chloride, intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 0.9% sodium chloride, intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 0.9% sodium chloride, intravenous

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-Care Coagulometer (investigational device)
Description: Perosphere Technologies' Point of Care (POC) Coagulometer Device will be used to measure whole blood clotting time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-Care Coagulometer (investigational device)
Description: Perosphere Technologies' Point of Care (POC) Coagulometer Device will be used to measure whole blood clotting time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-Care Coagulometer (investigational device)
Description: Perosphere Technologies' Point of Care (POC) Coagulometer Device will be used to measure whole blood clotting time.
Study: NCT05279651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
Study: NCT06037161

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Incisor root coverage procedure
Description: Mucogingival procedure to cover mandibular incisor tooth with receded gums

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular Incisor root coverage procedure
Description: Mucogingival procedure to cover mandibular incisor tooth with receded gums
Study: NCT06493864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B16D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06442943

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Multi-domain Cognitive Intervention
Description: * Cognitive rehabilitation includes home-based exercise, three times per week, for 30 minutes each session.~  * Cognitive stimulation involves art therapy, once a week, for 90 minutes per session.~    * Cognitive training encompasses memory, attention, executive function, and visuospatial training, conducted three times per week, with each session lasting 30 minutes.~      * Health education, once a week, covering the prevention and treatment of chronic diseases in the elderly, as well as healthy lifestyles for the elderly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-domain Cognitive Intervention
Description: * Cognitive rehabilitation includes home-based exercise, three times per week, for 30 minutes each session.~  * Cognitive stimulation involves art therapy, once a week, for 90 minutes per session.~    * Cognitive training encompasses memory, attention, executive function, and visuospatial training, conducted three times per week, with each session lasting 30 minutes.~      * Health education, once a week, covering the prevention and treatment of chronic diseases in the elderly, as well as healthy lifestyles for the elderly.
Study: NCT05954676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CareOrbit
Description: CareOrbit is a third-party organization that provides a HIPAA-compliant, patient-centered digital engagement platform that helps create, organize, and update content to educate and serve the patient and caregivers through their entire treatment journey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CareOrbit
Description: CareOrbit is a third-party organization that provides a HIPAA-compliant, patient-centered digital engagement platform that helps create, organize, and update content to educate and serve the patient and caregivers through their entire treatment journey.
Study: NCT06522620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Femoral Cutaneous Nerve Combined With Proximal Sciatic and Saphenous Nerve Block
Description: All nerve blocks were performed under ultrasound guidance，single supragluteal approach sciatic nerve block using a nerve stimulator, 20 ml of drug was injected around the sciatic nerve, the extent of drug diffusion was observed, the needle tip was turned into the deep surface of the gluteus maximus muscle below the deep gluteal artery and 5 ml of drug was injected, followed by a retractile canal saphenous nerve block injected with 15 ml of drug, and the difference in sensation of the posterior thighs of the bilateral thighs was measured after 15 min to ensure posterior femoral cutaneous nerve were blocked

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple Sciatic and Saphenous Nerve Blocks
Description: All nerve blocks were performed under ultrasound guidance，single subgluteal approach sciatic nerve block using a nerve stimulator, with 25 ml of drug injected around the sciatic nerve, followed by a retractile canal saphenous nerve block with 15 ml of drug injection
Study: NCT04335721

Intervention type: DRUG
Group type: OTHER
Intervention: Voxelotor
Description: Voxelotor 1500mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: Voxelotor 1500mg once a day
Study: NCT06513871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social perception tasks
Description: social perception tasks
Study: NCT05440942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be administered orally once daily via tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be administered orally once daily via tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be administered orally once daily via tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered orally twice daily (BID) via tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered orally twice daily (BID) via tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered orally twice daily (BID) via tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab will be administered intravenously (IV) on Day 8 of a 28-day cycle..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab will be administered intravenously (IV) on Day 8 of a 28-day cycle..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab will be administered intravenously (IV) on Day 8 of a 28-day cycle..
Study: NCT05246592

Intervention type: PROCEDURE
Intervention: Branches Sparing
Description: The patients will undergo axillary lymph node dissection with preserved axillary vein branches

Intervention type: PROCEDURE
Intervention: Branches Sparing
Description: The patients will undergo axillary lymph node dissection with preserved axillary vein branches

Intervention type: PROCEDURE
Intervention: None Branches Sparing
Description: The patients will undergo axillary lymph node dissection without preserved axillary vein branches

Intervention type: PROCEDURE
Intervention: None Branches Sparing
Description: The patients will undergo axillary lymph node dissection without preserved axillary vein branches
Study: NCT05561478

Intervention type: DEVICE
Intervention: Implantation of Synthesis Plus IOL (control device)
Description: Synthesis Plus IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients.

Intervention type: DEVICE
Intervention: Implantation of Synthesis Plus Toric IOL (investigational device)
Description: Synthesis Plus Toric IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients with pre-existing astigmatism.
Study: NCT05138757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: A prebiotic is a purified fiber of plant origin that has digestive health benefits by fostering the growth of beneficial microbes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo is a substance that has no therapeutic effects used as a control while testing new drugs.
Study: NCT05855798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Bupivacaine is a local anesthetic agent commonly used in ESP block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Bupivacaine is a local anesthetic agent commonly used in ESP block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Bupivacaine is a local anesthetic agent commonly used in ESP block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Magnesium is an adjuvant agent that can be added to the local anesthetic agent to increase analgesic effectiveness..

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Ketamine Hydrochloride is an also adjuvant agent that can be added to the local anesthetic to increase analgesic effectiveness.
Study: NCT04895839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Empowerment Program
Description: The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips.